CL2010000395A1 - Composicion farmaceutica que comprende dabigatran, inhibidor directo de la trombina y uno o mas inhibidores de plaquetas seleccionado entre clopidogrel y ticlopidina; y su uso para tratar enfermedades tales como trombosis venosa profunda y embolia pulmonar, entre otros eventos troboticos.8divisional de la solictud 687-06) - Google Patents

Composicion farmaceutica que comprende dabigatran, inhibidor directo de la trombina y uno o mas inhibidores de plaquetas seleccionado entre clopidogrel y ticlopidina; y su uso para tratar enfermedades tales como trombosis venosa profunda y embolia pulmonar, entre otros eventos troboticos.8divisional de la solictud 687-06)

Info

Publication number
CL2010000395A1
CL2010000395A1 CL2010000395A CL2010000395A CL2010000395A1 CL 2010000395 A1 CL2010000395 A1 CL 2010000395A1 CL 2010000395 A CL2010000395 A CL 2010000395A CL 2010000395 A CL2010000395 A CL 2010000395A CL 2010000395 A1 CL2010000395 A1 CL 2010000395A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
events
trobotic
dabigatran
ticlopidine
Prior art date
Application number
CL2010000395A
Other languages
English (en)
Inventor
Paul A Reilly
James C Gilbert
Thomas H Mueller
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36423564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2010000395(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2010000395A1 publication Critical patent/CL2010000395A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición farmacéutica que comprende un inhibidor de trombina, opcionalmente en forma de tautómeros, racematos, enantiomeros, diastereomeros, sales de adición y que comprende uno o más inhibidores de plaquetas; y su uso para tratar enfermedades tales como trombosis venosa profunda, embolia pulmonar, otros eventos trombóticos en pacientes de riesgo.
CL2010000395A 2005-03-29 2010-04-21 Composicion farmaceutica que comprende dabigatran, inhibidor directo de la trombina y uno o mas inhibidores de plaquetas seleccionado entre clopidogrel y ticlopidina; y su uso para tratar enfermedades tales como trombosis venosa profunda y embolia pulmonar, entre otros eventos troboticos.8divisional de la solictud 687-06) CL2010000395A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05006711 2005-03-29

Publications (1)

Publication Number Publication Date
CL2010000395A1 true CL2010000395A1 (es) 2010-08-20

Family

ID=36423564

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2010000395A CL2010000395A1 (es) 2005-03-29 2010-04-21 Composicion farmaceutica que comprende dabigatran, inhibidor directo de la trombina y uno o mas inhibidores de plaquetas seleccionado entre clopidogrel y ticlopidina; y su uso para tratar enfermedades tales como trombosis venosa profunda y embolia pulmonar, entre otros eventos troboticos.8divisional de la solictud 687-06)

Country Status (19)

Country Link
US (2) US20060222640A1 (es)
EP (1) EP1885354A2 (es)
JP (1) JP2008534552A (es)
KR (1) KR20070116936A (es)
CN (1) CN101151030A (es)
AR (1) AR056291A1 (es)
AU (1) AU2006228600A1 (es)
BR (1) BRPI0608656A2 (es)
CA (1) CA2602563A1 (es)
CL (1) CL2010000395A1 (es)
EA (1) EA015122B1 (es)
IL (1) IL186267A0 (es)
MX (1) MX2007010664A (es)
NO (1) NO20074149L (es)
NZ (1) NZ562775A (es)
TW (1) TW200722089A (es)
UA (1) UA92603C2 (es)
WO (1) WO2006103206A2 (es)
ZA (1) ZA200706698B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8906894B1 (en) 2000-07-27 2014-12-09 Thomas N. Thomas Methods for preventing and treating thrombotic disorders
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
IL159273A0 (en) * 2003-12-09 2004-06-01 Transpharma Medical Ltd Transdermal delivery system for sustained release of polypeptides
EP1888001B1 (en) * 2005-06-10 2014-08-06 Syneron Medical Ltd. Patch for transdermal drug delivery
CA2657269A1 (en) * 2006-07-17 2008-01-24 Boehringer Ingelheim International Gmbh New indications for direct thrombin inhibitors
US20100087488A1 (en) * 2006-10-10 2010-04-08 Boehringer Ingelheim International Gmgh Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
US20100293807A1 (en) * 2007-10-29 2010-11-25 Transpharma Medical, Ltd. Vertical patch drying
US20110236405A1 (en) * 2008-07-29 2011-09-29 Tel Hashomer Medical Research Infrastructure And Services Ltd. Coagulation factor modulation for controlling transplant organ size
WO2010029552A1 (en) * 2008-09-10 2010-03-18 Transpharma Medical Ltd. Transdermal delivery of oligosaccharides
CN102209546A (zh) * 2008-11-11 2011-10-05 贝林格尔.英格海姆国际有限公司 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良有效性的方法
CA2738885A1 (en) * 2008-11-11 2010-05-20 Boehringer Ingelheim International Gmbh Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
CN102209544A (zh) * 2008-11-11 2011-10-05 贝林格尔.英格海姆国际有限公司 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良安全性的方法
EP2384196B1 (en) 2008-12-30 2017-09-13 Johansson, Pär Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
CA2825252C (en) 2011-01-25 2018-10-16 Universite Catholique De Louvain Compositions of an antithrombin activator and a thrombin inhibitor for use in cell transplantation
CN102250099B (zh) * 2011-05-16 2013-10-16 中国药科大学 一类非肽类抗凝血酶抑制剂、其制法以及医药用途
US9775890B2 (en) 2012-01-25 2017-10-03 Université Catholique de Louvain Factor Xa inhibitor used with liver-derived progenitor cells
US20130345262A1 (en) 2012-06-25 2013-12-26 Boehringer Ingelheim International Gmbh Method for prevention of stroke
WO2014060561A1 (en) * 2012-10-19 2014-04-24 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral pharmaceutical formulations comprising dabigatran
EP2722033A1 (en) * 2012-10-19 2014-04-23 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical Compositions of Dabigatran Free Base
WO2015001124A1 (en) 2013-07-05 2015-01-08 Université Catholique de Louvain Conditioned medium from human adult liver stem cells and its use in the treatment of liver disorders
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
CN105250286A (zh) * 2015-11-13 2016-01-20 谭惠娟 一种抗血栓组合物
CN108236612A (zh) * 2016-12-27 2018-07-03 李志忠 用于冠脉介入手术中抗凝的组合产品及其用途
WO2020180489A1 (en) * 2019-03-06 2020-09-10 University Of Rochester Anticoagulant compositions and uses thereof
US11654036B2 (en) 2020-05-26 2023-05-23 Elixir Medical Corporation Anticoagulant compounds and methods and devices for their use

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) * 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
NZ286082A (en) * 1995-03-15 1998-09-24 Behringwerke Ag Method of treating acute myocardial infarction with hirudin and acetylsalicylic acid in patients not undergoing thrombolytic treatment
FR2744918B1 (fr) * 1996-02-19 1998-05-07 Sanofi Sa Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) * 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
DE19834751A1 (de) * 1998-08-01 2000-02-03 Boehringer Ingelheim Pharma Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel
GB9930540D0 (en) * 1999-12-23 2000-02-16 Rhone Poulenc Rorer Pharma Chemical compounds
GB0014134D0 (en) * 2000-06-10 2000-08-02 Astrazeneca Ab Combination therapy
CN100398104C (zh) * 2001-09-14 2008-07-02 三菱制药株式会社 抗血栓药和吡唑啉酮衍生物的组合药物
JP3866715B2 (ja) * 2002-03-07 2007-01-10 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステル及びその塩の経口適用の投与形態
DE10235639A1 (de) * 2002-08-02 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel
WO2004093881A2 (en) * 2003-04-24 2004-11-04 Boehringer Ingelheim International Gmbh Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors

Also Published As

Publication number Publication date
EA200701841A1 (ru) 2008-02-28
EP1885354A2 (en) 2008-02-13
WO2006103206A3 (en) 2007-01-11
EA015122B1 (ru) 2011-06-30
ZA200706698B (en) 2008-12-31
WO2006103206A2 (en) 2006-10-05
MX2007010664A (es) 2007-12-12
AU2006228600A1 (en) 2006-10-05
KR20070116936A (ko) 2007-12-11
CA2602563A1 (en) 2006-10-05
AR056291A1 (es) 2007-10-03
NZ562775A (en) 2011-03-31
TW200722089A (en) 2007-06-16
IL186267A0 (en) 2008-01-20
UA92603C2 (ru) 2010-11-25
US20100184729A1 (en) 2010-07-22
BRPI0608656A2 (pt) 2010-01-19
CN101151030A (zh) 2008-03-26
JP2008534552A (ja) 2008-08-28
US20060222640A1 (en) 2006-10-05
NO20074149L (no) 2007-12-11

Similar Documents

Publication Publication Date Title
CL2010000395A1 (es) Composicion farmaceutica que comprende dabigatran, inhibidor directo de la trombina y uno o mas inhibidores de plaquetas seleccionado entre clopidogrel y ticlopidina; y su uso para tratar enfermedades tales como trombosis venosa profunda y embolia pulmonar, entre otros eventos troboticos.8divisional de la solictud 687-06)
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
CR9875A (es) Inhibidores de dipeptidilo peptidasa para tratar diabetes
ECSP077980A (es) Inhibidores de la actividad akt
EA200901486A1 (ru) СОЕДИНЕНИЯ И КОМПОЗИЦИИ, КАК ИНГИБИТОРЫ КИНАЗЫ c-KIT И PDGFR
EA200870019A1 (ru) Лактамовые соединения и способы их применения
ATE464303T1 (de) Als inhibitoren von rock und anderen proteinkinasen geeignete zusammensetzungen
NO20074431L (no) Pyrrolopyrimidiner nyttige som proteinkinaseinhibitorer
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
NO20072567L (no) Triazoler nyttige som proteinkinase-inhibitorer
CO6440551A2 (es) Compuestos pirazolo[1,5-a]pirimidina sustituida como inhibidores de trk cinasa
ECSP099376A (es) Inhibidores de la actividad de la akt
DOP2002000438A (es) Inhibidores de la dipetidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes
CR11499A (es) Compuestos que contienen quinoxalina como inhibidores del virus de la hepatitis c
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
DE602005019971D1 (de) Inhibitoren von cysteinprotease
NO20071078L (no) Antivirale forbindelser
UY27712A1 (es) Indazoles sustituidos, composiciones que los contienen, procedimientos de fabricación y utilización
ATE456571T1 (de) Proteasom-hemmer und verwendungsverfahren dafür
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
NO20082120L (no) Behandling og forebyggelse av mikroangiopati
WO2012135697A3 (en) Novel rho kinase inhibitors and methods of use
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
TN2009000451A1 (en) Intrvenous and oral dosing of a direct-acting and reversible p2y12 inhibitor